NOTCH2 and neoplasm: Further, in the tumor-draining LN (TDLN), tumor-specific Vβ8.1/2+ CD8+ T cells representing a frequency of 8-10% (data not shown) showed increased expression of the surface receptor and mRNA of Notch1 and Notch2 following bortezomib treatment (Figure 7B and 7C).